Liquidia Corporation
As of Oct 22, 2026, Liquidia is in Stage 3, the topping phase, now in week 6 (since Sep 14, 2026). It closed at $39.69, 56.4% below its 52-week high and below its 200-day average, which is rising.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LQDA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LQDA among Drug Manufacturers - Specialty & Generic11th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …11 | LQDA | Stage 3 · wk 6 | 91 | −41.2% |
Liquidia: quick answers
What stage is Liquidia in?
As of Oct 22, 2026, Liquidia (LQDA) is in Stage 3, the topping phase. It entered Stage 3 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Liquidia in an uptrend?
Its uptrend has stalled. Liquidia is in Stage 3, the topping phase that follows an advance. It trades 26.5% below its 200-day average, which is rising.
How far is Liquidia from its 52-week high?
Liquidia closed at $39.69 on Oct 22, 2026, 56.4% below its 52-week high of $91.03. Its 52-week low is $22.02.
How has Liquidia performed over the past year?
As of Oct 22, 2026, Liquidia is up 68.2% over the past year and up 26.4% so far in 2026.
Which sector and industry is Liquidia in?
Liquidia is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.